Solid state forms of 5-azacytidine and processes for preparation thereof
The present invention provides novel crystalline forms of 5-deazacytidine, and pharmaceutical compositions comprising these novel forms. The invention also provides methods for the preparation of the novel forms and compositions.
1. 5-Azacytidine containing about 10 ppm to about 2000 ppm of non-volatile solvents.
2. The 5-azacytidine of claim 1 containing about 10 ppm to about 500 ppm of non-volatile solvents.
3. The 5-azacytidine of claim 1 , wherein said 5-azacytidine is crystalline 5-azacytidine characterized by data selected from the group consisting of: a PXRD pattern with peaks at about 12.2, 13.1, 14.4, 16.2, and 23.1±0.2 degrees two-theta, a PXRD pattern as depicted in FIG. 13 , and a combination thereof, said crystalline 5-azacytidine containing less than about 5% by weight of a crystalline 5-azacytidine having most prominent diffractions at PXRD at two theta values at 6.566, 11.983, 13.089, 15.138, 17.446, 20.762, 21.049, 22.776, 24.363, 25.743, 26.305, 28.741, 31.393, 32.806, 33.043, 33.536, 36.371, 39.157, and 41.643 degrees two-theta, and less than about 5% by weight of a crystalline 5-azacytidine having most prominent PXRD diffractions at 13.4, 17.6, and 22.1 degrees two-theta.
4. A method for preparing the 5-azacytidine of claim 1 comprising heating a suspension of 5-azacytidine in a single polar organic solvent selected from the group consisting of: an aliphatic alcohol, a nitrile, an ether, nitromethane, pyridine, or in a mixture of solvents comprising said polar organic solvent and a non-polar organic solvent selected from the group consisting of: a ketone, a hydrocarbon, or an ester, and recovering 5-azacytidine containing about 10 ppm to about 2000 ppm of non-volatile solvents; wherein the single polar solvent or its mixture with a non-polar solvent has boiling point of less than 140° C.
5. The method of claim 4 , wherein the obtained 5-azacytidine is crystalline 5-azacytidine characterized by data selected from the group consisting of: a PXRD pattern with peaks at about 12.2, 13.1, 14.4, 16.2, and 23.1±0.2 degrees two-theta, a PXRD pattern as depicted in FIG. 13 , and a combination thereof containing less than about 5% by weight of a crystalline 5-azacytidine having most prominent diffractions at PXRD at two theta values at 6.566, 11.983, 13.089, 15.138, 17.446, 20.762, 21.049, 22.776, 24.363, 25.743, 26.305, 28.741, 31.393, 32.806, 33.043, 33.536, 36.371, 39.157, and 41.643 degrees two-theta, and less than about 5% by weight of a crystalline 5-azacytidine having most prominent PXRD diffractions at 13.4, 17.6, and 22.1 degrees two-theta.
6. The method of claim 4 , wherein the starting 5-azacytidine is selected from the group consisting of: crude 5-azacytidine, crystalline 5-azacytidine having the most prominent PXRD diffractions at 2theta angles at 5.704, 11.571, 12.563, 14.070, 15.943, 16.993, 18.066, 20.377, 20.729, 21.484, 21.803, 22.452, 22.709, 23.646, 24.068, 25.346, 25.346, 26.900, 27.991, 28.527, 28.723, 30.124, 30.673, 31.059, 35.059, 38.195 and 38.403, crystalline 5-azacytidine characterized by data selected from the group consisting of: a PXRD pattern with peaks at about 8.7, 9.5, 12.1, 14.4 and 17.3±0.2 degrees two-theta; a PXRD pattern as depicted in FIG. 1 ; a solid-state 13 C NMR spectrum having signals with chemical shifts at about 166.2, 155.9, and 154.2±0.2 ppm; a solid-state 13 C NMR spectrum as depicted in FIG. 2 ; a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 90 to 180 ppm of about 60.5, 62.2, and 72.5±0.1 ppm, and a combination thereof, crystalline 5-azacytidine which exhibits distinctive PXRD peaks at 5.8, 11.5, 12.8, 22.4, and 26.6 degrees two-theta, and crystalline 5-azacytidine having most prominent diffractions on PXRD at two theta values at 6.566, 11.983, 13.089, 15.138, 17.446, 20.762, 21.049, 22.776, 24.363, 25.743, 26.305, 28.741, 31.393, 32.806, 33.043, 33.536, 36.371, 39.157, and 41.643 degrees two-theta.
7. The method of claim 4 , wherein the suspension of 5-azacytidine is provided by combining 5-azacytidine and a single polar organic solvent or with a mixture of solvents comprising said single polar organic solvent and a non-polar organic solvent.
8. The method of claim 7 , wherein the aliphatic alcohol is a C 2-6 aliphatic alcohol, the nitrile is C 2-4 nitrile, and the ether is a C 3-8 ether including penta or hexa-cyclic ether.
9. The method of claim 8 , wherein the C 2-6 aliphatic alcohol is methanol, ethanol, 2-propanol, 1-propanol, 1-butanol, 2-butanol, i-butanol, amylalcohol, methoxyethanol, ethoxyethanol or mixtures thereof, the C 2-4 nitrile is acetonitrile, and the C 3-8 ether including penta or hexa-cyclic ether is dimethoxyethane, tert-butylmethylether, dioxolane, tetrahydrofuran, methyl-tetrahydrofuran, or dioxane.
10. The method of claim 9 , wherein the C 2-6 aliphatic alcohol is 1-butanol or ethanol.
11. The method of claim 9 , wherein the C 3-8 ether including penta or hexa-cyclic ether is 1,4-dioxane.
12. The method of claim 4 , wherein the ketone is a C 3-6 ketone, the ester is a C 2-6 ester, and the hydrocarbon is a C 6-10 hydrocarbon.
13. The method of claim 12 , wherein the C 3-6 ketone is acetone, methyl-ethylketone, or methylbutylketone, the C 2-6 ester is ethylacetate, propyl acetate, isopropyl acetate, butylacetate, or isobutylacetate, and the C 6-10 hydrocarbon is hexane, heptane, cyclo-hexane, methylcyclohexane, toluene, m-xylene, p-xylene, or chlorobenzene.
14. The method of claim 13 , wherein the C 3-6 ketone is methylethyl ketone or methylisobutyl ketone, the C 2-6 ester is ethylacetate, and the C 6-10 hydrocarbon is toluene.
15. The method of claim 4 , wherein the solvent used to prepare the suspension is a single polar organic solvent, selected from ethanol and 1-butanol.
16. The method of claim 4 , wherein the suspension is heated to a temperature of about 30° C. to about 130° C.
17. Crystalline 5-azacytidine
characterized by data selected from the group consisting of: a PXRD pattern with peaks at about 9.4, 11.8, 12.1, 14.3 and 16.5±0.2 degrees two-theta; a PXRD pattern as depicted in FIG. 9 ; a solid-state 13 C NMR spectrum having signals with chemical shifts at about 166.6, 154.3, and 93.9±0.2 ppm; a solid-state 13 C NMR spectrum having signals with chemical shifts at about 166.6, 155.8, and 93.9±0.2 ppm; a solid-state 13 C NMR spectrum as depicted in FIG. 10 ; a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 90 to 180 ppm of about 60.4 and 72.7° 0.1 ppm, a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 90 to 180 ppm of about 61.9 and 72.7±0.1 ppm, and combinations thereof.
18. The crystalline 5-azacytidine according to claim 17 , characterized by data a PXRD pattern with peaks at about 9.4, 11.8, 12.1, 14.3 and 16.5±0.2 degrees two-theta.
19. The crystalline 5-azacytidine according to claim 18 , characterized by a PXRD pattern as depicted in FIG. 9 .
20. The crystalline 5-azacytidine according to claim 17 , characterized by a solid-state 13 C NMR spectrum as depicted in FIG. 10 .